Literature DB >> 17828582

NF-kappaB controls growth of glioblastomas/astrocytomas.

Denise Smith1, Takeshi Shimamura, Stephanie Barbera, Bruce E Bejcek.   

Abstract

NF-kappaB is a family of transcription factors that have been shown to be elevated in a variety of tumor types and in some cases central to their survival and growth. Here we present evidence that U-87 MG and U-118 MG growth is regulated by NF-kappaB and controlled by PDGF. NF-kappaB activity was suppressed by a dominant negative mutant of the human PDGF type beta receptor and PDGF-B chain neutralizing antibodies. Creation of cell lines that had inducible expression of shRNAs directed against either c-Rel or RelA inhibited growth almost 90% indicating that NF-kappaB plays a central role in glioblastoma growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828582     DOI: 10.1007/s11010-007-9593-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  58 in total

Review 1.  NF-kappaB signaling pathways in mammalian and insect innate immunity.

Authors:  N Silverman; T Maniatis
Journal:  Genes Dev       Date:  2001-09-15       Impact factor: 11.361

2.  Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma.

Authors:  Shoichi Nagai; Kazuo Washiyama; Masanori Kurimoto; Akira Takaku; Shunro Endo; Toshiro Kumanishi
Journal:  J Neurosurg       Date:  2002-05       Impact factor: 5.115

3.  Identification of Tyr-762 in the platelet-derived growth factor alpha-receptor as the binding site for Crk proteins.

Authors:  K Yokote; U Hellman; S Ekman; Y Saito; L Rönnstrand; Y Saito; C H Heldin; S Mori
Journal:  Oncogene       Date:  1998-03-12       Impact factor: 9.867

4.  Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

Authors:  U Kordes; D Krappmann; V Heissmeyer; W D Ludwig; C Scheidereit
Journal:  Leukemia       Date:  2000-03       Impact factor: 11.528

5.  The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp.

Authors:  A Kazlauskas; G S Feng; T Pawson; M Valius
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

6.  Direct interaction between Shc and the platelet-derived growth factor beta-receptor.

Authors:  K Yokote; S Mori; K Hansen; J McGlade; T Pawson; C H Heldin; L Claesson-Welsh
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

7.  Phosphorylation sites at the C-terminus of the platelet-derived growth factor receptor bind phospholipase C gamma 1.

Authors:  A Kashishian; J A Cooper
Journal:  Mol Biol Cell       Date:  1993-01       Impact factor: 4.138

8.  A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase.

Authors:  W Li; R Nishimura; A Kashishian; A G Batzer; W J Kim; J A Cooper; J Schlessinger
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

9.  I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding.

Authors:  P A Ganchi; S C Sun; W C Greene; D W Ballard
Journal:  Mol Biol Cell       Date:  1992-12       Impact factor: 4.138

10.  Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells.

Authors:  S M Shamah; C D Stiles; A Guha
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

View more
  27 in total

Review 1.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

2.  The deadly connection between endoplasmic reticulum, Ca2+, protein synthesis, and the endoplasmic reticulum stress response in malignant glioma cells.

Authors:  Guyla G Johnson; Misti C White; Jian-He Wu; Matthew Vallejo; Maurizio Grimaldi
Journal:  Neuro Oncol       Date:  2014-02-24       Impact factor: 12.300

Review 3.  NF-kappaB and STAT3 signaling in glioma: targets for future therapies.

Authors:  George P Atkinson; Susan E Nozell; Etty Tika N Benveniste
Journal:  Expert Rev Neurother       Date:  2010-04       Impact factor: 4.618

4.  Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network.

Authors:  Kristen M Holmes; Matti Annala; Corrine Y X Chua; Sarah M Dunlap; Yuexin Liu; Niek Hugen; Lynette M Moore; David Cogdell; Limei Hu; Matti Nykter; Kenneth Hess; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-15       Impact factor: 11.205

5.  Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.

Authors:  Tsuyoshi Fukushima; Makiko Kawaguchi; Kenji Yorita; Hiroyuki Tanaka; Hideo Takeshima; Kazuo Umezawa; Hiroaki Kataoka
Journal:  Neuro Oncol       Date:  2011-10-03       Impact factor: 12.300

6.  Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-κB expressions may play an important role in silibinin-induced response.

Authors:  Meysam Yousefi; Seyed H Ghaffari; Bahram M Soltani; Shahriar Nafissi; Majid Momeny; Ali Zekri; Mehrdad Behmanesh; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Neurochem Res       Date:  2012-06-21       Impact factor: 3.996

7.  Suicidal gene therapy in an NF-κB-controlled tumor environment as monitored by a secreted blood reporter.

Authors:  C E Badr; J M Niers; D Morse; J A Koelen; P Vandertop; D Noske; T Wurdinger; P A Zalloua; B A Tannous
Journal:  Gene Ther       Date:  2010-12-09       Impact factor: 5.250

8.  Targeting A20 decreases glioma stem cell survival and tumor growth.

Authors:  Anita B Hjelmeland; Qiulian Wu; Sarah Wickman; Christine Eyler; John Heddleston; Qing Shi; Justin D Lathia; Jennifer Macswords; Jeongwu Lee; Roger E McLendon; Jeremy N Rich
Journal:  PLoS Biol       Date:  2010-02-23       Impact factor: 8.029

9.  Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models.

Authors:  Christian E Badr; Johanna M Niers; Lee-Ann Tjon-Kon-Fat; David P Noske; Thomas Wurdinger; Bakhos A Tannous
Journal:  Mol Imaging       Date:  2009 Sep-Oct       Impact factor: 4.488

10.  Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.

Authors:  Tara A Barone; Catherine A Burkhart; Alfiya Safina; Gary Haderski; Katerina V Gurova; Andrei A Purmal; Andrei V Gudkov; Robert J Plunkett
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.